Published: 30 November 2019
Author(s): Christof Aigner, Georg A. Böhmig, Farsad Eskandary, Harald Herkner, Zoltán Prohászka, Dorottya Csuka, Renate Kain, Martina Gaggl, Raute Sunder-Plassmann, Thomas Müller-Sacherer, André Oszwald, Gottfried Fischer, Alice Schmidt, Gere Sunder-Plassmann
Atypical hemolytic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA) that can lead to end-stage renal disease (ESRD) (1). Without preemptive therapy early recurrence after kidney transplantation results in allograft loss in 50% of patients within 5 years (2,3).
